Guality eradication anti-helicobacter therapy increases the effectiveness of treatment of patients with stable angina pectoris
https://doi.org/10.31146/1682-8658-ecg-186-2-41-46
Abstract
Aim. On the basis of the complex analysis, to evaluate the efficiency of eradication therapy at patients with stable stenocardia with a combination of chronic gastritis. Material and methods. 46 patients with stable stenocardia with a combination of chronic H. pylori-associated gastritis were included in the open prospective clinical study. Two groups of patients were formed during the study. Patients of group I (n = 25) received eradication therapy in accordance with antibiotic sensitivity of H. pylori strains, patients of group II (n = 21) - without antibiotic sensitivity. In all patients before and after treatment were performed: evaluation of clinical status, laboratory indicators, EGDS with biopsy sampling, diagnosis of H. pylori. Results. The effectiveness of eradication therapy was 86.9%, at the same time, 96% -in group I and 76.2% - in group II. It is established: stabilization of clinical status of patients, improvement of morphological and endoscopic picture of gastroduodenal zone, improvement of laboratory indices. Conclusions. The inclusion of antibiotic-sensitive erication therapy in the algorithm of treatment of patients with stable stenocardia in combination with chronic gastritis allows to achieve high effectiveness of killing the infection Helicobacter pylori. At the same time stabilizes clinical status of patients, laboratory indices, has a positive effect on morphological and endoscopic picture of gastroduodenal zone, preventing progression of metaplastic changes.
About the Authors
M. N. Prikhodko
Kirov state medical university of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Zh. G. Simonova
Kirov state medical university of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
E. P. Kolevatykh
Kirov state medical university of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Jafarzadeh A., Esmaeeli-Nadimi A., Nemati M., et al. Serum concentrations of Helicobacter pylori IgG and the virulence factor CagA in patients with ischemic heart disease. East. Mediterr. Health J. 2010, vol. 16, no. 10, pp. 1039-1044.
2. Niccoli G., Franceschi F., Cosentino N., et al. Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coron. Artery Dis. 2010, vol. 21, no. 4, pp. 217-221.
3. Pavlov O. N. Svyaz infekcii Helicobacter pylori i systemnogo vospaleniya u bolnyh s nestabilnym techeniem ishemicheskoy bolezni serdca [Connection of Helicobacter pylori infection and systemic inflammation in patients with unstable course of ischemic heart disease]. Applied medicine. 2012, vol. 58, no. 3, pp. 49-52. (In Russ.)@@ Павлов О. Н. Связь инфекции Helicobacter pylori и системного воспаления у больных с нестабильным течением ишемической болезни сердца. Практическая медицина. 2012, Т. 58, № 3, С. 49-52.
4. Prikhodko M. N., Andreev K. V., Simonov Zh. G. Osobennosty sostoyaniya obchych sonnych arteriy u bolnych stabylnoy stenocardiey pry sochetanii s gastroduodenalnoy patologiey [Peculiarities of the state of common carotid arteries in patients with stable angina when combined with gastroduodenal pathology]. Vyatka medical bulletin. 2017, vol. 55, no. 3, pp. 15-19. (In Russ.)@@ Приходько М. Н., Андреев К. В., Симонова Ж. Г. Особенности состояния общих сонных артерий у больных стабильной стенокардией при сочетании с гастродуоденальной патологией. Вятский медицинский вестник. 2017, Т. 55, № 3, С. 15-19.
5. Kaprin A. D., Starynsky V. V., Petrov G. V. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost i smertnost) [Malignant neoplasms in Russia in 2016 (morbidity and mortality)]. M.: MNIOI named after P. A. Hercen - branch of FSBU “NMIC Radiology” of the Ministry of Health of Russia, 2018, 250 p. (In Russ.)@@ Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). - М.: МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018, 250 с.
6. Simonova Zh.G., Martusevich A. K., Tarlovskaya E. I. Analysis of the clinical efficiency of eradication therapy in patients with coronary heart disease associated with gastroduodenal pathology. Therapeutic archive. 2017, vol. 89, no. 8, pp. 37-42. (In Russ.) DOI: 10.17116/terarkh201789837-42@@ Симонова Ж. Г., Мартусевич А. К., Тарловская Е. И. Анализ клинической эффективности эрадикационной терапии у больных ишемической болезнью сердца, ассоциированной с патологией гастродуоденальной зоны. Терапевтический архив. 2017, Т. 89, № 8, С. 37-42.
7. Graham D. Y., Lee Y. C., Wu M. S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clinical Gastroenterology and Hepatology. 2014, vol. 12, pp. 177-186. (In Russ.)
8. Prikhodko M. N., Prikhodko L. O., Kolevatykh E. P., Ikonnikov S. V., Simonov Z. G. Assessment of the antibiotic susceptibility of helicobacter pylori in patients with stable angina with concomitant gastroduodenal pathology. Experimental and Clinical Gastroenterology. 2018;(3):34-40. (In Russ.)@@ Приходько М. Н., Приходько Л. О., Колеватых Е. П., Иконников С. В., Симонова Ж. Г. Оценка антибиотикочувствительности Helicobacter pylori у больных стабильной стенокардией с сопутствующей гастродуоденальной патологией. Экспериментальная и клиническая гастроэнтерология. 2018, Т. 151, № 3, С. 34-40.
9. Simonov Zh.G., Martusevich A. K., Tarlovskaya E. I. Kliniko-gemodinamicheskaya characteristika effectivnosty eradikacionnoy terapii u bolnych s sochetaniem ishemicheskoy bolezni serdca i yazvennoy bolezni [Clinico-hemodynamic characteristic of the effectiveness of ericatory therapy in patients with a combination of ischemic heart disease and ulcer disease]. Archive of internal medicine. 2014, vol. 19, no. 5, pp. 71-75. (In Russ.)@@ Симонова Ж. Г., Мартусевич А. К., Тарловская Е. И. Клинико-гемодинамическая характеристика эффективности эрадикационной терапии у больных с сочетанием ишемической болезни сердца и язвенной болезни. Архив внутренней медицины. 2014, Т. 19, № 5. С. 71-75.
10. Tsukanov V. V., Tretiakov O. V., Amelchugova O. S., et al. Rasprostranennost atroficheskogo gastrita tela zheludka u naseleniya g. Krasnoyarska starshe 45 let [The prevalence of atrophic gastritis of the stomach body in the population of Krasnoyarsk is over 45 years old]. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012, no. 4, pp. 27-31. (In Russ.)@@ Цуканов В. В., Третьякова О. В., Амельчугова О. С. и др. Распространенность атрофического гастрита тела желудка у населения г. Красноярска старше 45 лет. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012, № 4, С. 27-31.
11. Shimanskaya A. G., Mosgovoy S. I., Nazarov A. N., et al. Atroficheskyi gastrit kak predrak: molekulyarnaya biologiya i problemy diagnoza [Atrophic gastritis as a precursor: molecular biology and diagnosis problems]. Prospects for the development of modern medicine. Voronezh. 2015, Issue II, pp. 139-141. (In Russ.)@@ Шиманская А. Г., Мозговой С. И., Назаров А. Н. и др. Атрофический гастрит как предрак: молекулярная биология и проблемы диагноза. Перспективы развития современной медицины. г. Воронеж. 2015, Выпуск II. С. 139-141.
12. Pavlov O. N. Nositelstvo Helicobacter pylori kak skrytyi systemniy factor riska [Wearing Helicobacter pylori as a hidden systemic risk factor]. Medical almanac. 2011, no. 4, pp. 125-130. (In Russ.)@@ Павлов О. Н. Носительство Helicobacter pylori как скрытый системный фактор риска. Мед.альманах. 2011, № 4, С. 125-130.
13. Kim Y. J., Chung J. W., Lee S. J., et al. Progression from Chronic Atrophic Gastritis to Gastric Cancer; Tangle, Toggle, Tackle with Korea Red Ginseng. J. Clin. Biochem. Nutr. 2010, vol. 46, no. 3, pp. 195-204.
14. Naylor G. M., Gotoda T., Dixon M., et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006, vol. 55, no. 11, pp. 1545-1552.
15. Roberts S. E., Morrison-Rees S., Samuel D. G., et al. Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment. Pharmacol. Ther. 2016, vol. 43, no. 3, pp. 334-345.
Review
For citations:
Prikhodko M.N., Simonova Zh.G., Kolevatykh E.P. Guality eradication anti-helicobacter therapy increases the effectiveness of treatment of patients with stable angina pectoris. Experimental and Clinical Gastroenterology. 2021;(2):41-46. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-186-2-41-46
Views:
379
Email this article 